Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
J Immunother Cancer. 2024 Jul 20;12(7):e009309. doi: 10.1136/jitc-2024-009309.
The widespread use of immune checkpoint inhibitors (ICIs) in clinical practice has broadened our understanding of their immune-related adverse events (irAEs). IrAEs, including musculoskeletal adverse events, remain a significant concern. While ICI-associated arthritis is a well-documented musculoskeletal side effect of ICI therapy, the direct effects of ICIs on bone in patients with cancer are poorly understood. There is emerging evidence to support the hypothesis that ICIs adversely impact bone turnover and can lead to osteoporosis and fragility fractures, which are not currently recognized as irAEs.
免疫检查点抑制剂（ICIs）在临床实践中的广泛应用拓宽了我们对其免疫相关不良事件（irAEs）的认识。irAEs，包括肌肉骨骼不良事件，仍然是一个重要的关注点。虽然与 ICI 相关的关节炎是 ICI 治疗的一种有充分文献记载的肌肉骨骼副作用，但 ICI 对癌症患者骨骼的直接影响还知之甚少。有越来越多的证据支持这样一种假设，即 ICI 会对骨代谢产生不利影响，并导致骨质疏松症和脆性骨折，而这些目前尚未被认为是 irAEs。
